We are live on ! Find out more
PCRX icon

Pacira BioSciences
PCRX

211 hedge funds and large institutions have $1.72B invested in Pacira BioSciences in 2019 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 71 increasing their positions, 61 reducing their positions, and 46 closing their positions.

New
Increased
Maintained
Reduced
Closed

61% more call options, than puts

Call options by funds: $6.54M | Put options by funds: $4.05M

16% more repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 61

4.78% more ownership

Funds ownership: 103.6% → 108.38% (+4.8%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

9% less first-time investments, than exits

New positions opened: 42 | Existing positions closed: 46

3% less funds holding

Funds holding: 218 → 211 (-7)

8% less capital invested

Capital invested by funds: $1.86B → $1.72B (-$141M)

Holders
211
Holders Change
-7
Holders Change %
-3.21%
% of All Funds
4.63%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.13%
New
42
Increased
71
Reduced
61
Closed
46
Calls
$6.54M
Puts
$4.05M
Net Calls
+$2.49M
Net Calls Change
+$722K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$137M
2
ACA
Avoro Capital Advisors
New York
+$47.9M
3
PC
Paulson & Co
New York
+$30.2M
4
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
+$21M
5
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$20.6M

Top Sellers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
-$122M
2
Millennium Management
Millennium Management
New York
-$33.7M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$33.3M
4
PHS
PFM Health Sciences
California
-$31.9M
5
Deutsche Bank
Deutsche Bank
Germany
-$20.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
PHK
176
Point72 Hong Kong
Hong Kong
$47K +$29.3K +735 +146%
RA
177
Royce & Associates
New York
$40K +$42.3K +1,060 New
FCA
178
FinTrust Capital Advisors
South Carolina
$28K +$4.95K +124 +20%
OAM
179
Oppenheimer Asset Management
New York
$27K -$281K -7,049 -91%
ATC
180
Adirondack Trust Company
New York
$23K – – –
SMG
181
Spectrum Management Group
Indiana
$23K – – –
HPC
182
HM Payson & Co
Maine
$19K -$16K -400 -44%
CFB
183
Cullen/Frost Bankers
Texas
$19K – – –
MAM
184
Meeder Asset Management
Ohio
$18K -$226K -5,658 -92%
GRP
185
Global Retirement Partners
California
$13K – – –
MGI
186
MayTech Global Investments
New York
$11K – – –
Daiwa Securities Group
187
Daiwa Securities Group
Japan
$10K – – –
Acadian Asset Management
188
Acadian Asset Management
Massachusetts
$9K +$9.94K +249 New
EW
189
Evoke Wealth
California
$8.64K +$9.06K +227 New
FGAM
190
Financial Gravity Asset Management
Texas
$8K – – –
GI
191
Gradient Investments
Minnesota
$8K – – –
NCM
192
New Capital Management
Texas
$8K – – –
Rockefeller Capital Management
193
Rockefeller Capital Management
New York
$8K +$7.98K +200 New
ASN
194
Advisory Services Network
Georgia
$7K – – –
VFA
195
Valeo Financial Advisors
Indiana
$7K +$2.55K +64 +49%
GWM
196
Geneos Wealth Management
Colorado
$6K – – –
CFA
197
Carroll Financial Associates
North Carolina
$5K – – –
HI
198
Human Investing
Oregon
$5K – – –
CAL
199
Capital Analysts LLC
Pennsylvania
$3K – – –
FRA
200
Front Row Advisors
California
$3K – – –
6 7
8
9 10

PCRX Hedge Fund Activity: Q3 2019 in Review

211 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q3 2019, worth a combined $1.72B — down 7.6% from $1.86B a quarter earlier.

Sellers outnumbered buyers: 46 funds closed out of PCRX and 42 opened new positions — a net loss of 4 holders — while 61 trimmed existing stakes and 71 added.

The largest buyer was BlackRock, adding an estimated $137M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $122M sold.

  • 211 institutional investors held Pacira BioSciences (PCRX) as of Q3 2019, down from 218 in Q2 2019.
  • Funds reported $1.72B of Pacira BioSciences stock for Q3 2019, down 7.6% quarter-over-quarter.
  • 42 funds opened new Pacira BioSciences positions in Q3 2019 and 46 closed out, a net change of -4 holders.
  • The largest Pacira BioSciences buyer in Q3 2019 was BlackRock, an estimated $137M added.
  • The largest Pacira BioSciences seller in Q3 2019 was Consonance Capital Management, an estimated $122M sold.

Based on aggregated 13F filings for Q3 2019.